Cite

HARVARD Citation

    Riudavets, M. et al. (2022). Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations. European journal of cancer. pp. 142-148. [Online]. 
  
Back to record